JP2000214150A - Analyzer for lipoprotein - Google Patents
Analyzer for lipoproteinInfo
- Publication number
- JP2000214150A JP2000214150A JP11016779A JP1677999A JP2000214150A JP 2000214150 A JP2000214150 A JP 2000214150A JP 11016779 A JP11016779 A JP 11016779A JP 1677999 A JP1677999 A JP 1677999A JP 2000214150 A JP2000214150 A JP 2000214150A
- Authority
- JP
- Japan
- Prior art keywords
- cholesterol
- lipoprotein
- sample
- triglyceride
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術】本発明は、血清、血漿、細胞培養
上清などの試料中に含まれるリポ蛋白質を分析するため
の装置に関する。The present invention relates to an apparatus for analyzing lipoproteins contained in samples such as serum, plasma, cell culture supernatant and the like.
【0002】[0002]
【従来の技術】リポ蛋白質は、コレステロール、トリグ
リセリド(中性脂肪)、リン脂質及びアポ蛋白質が会合
した物質で、時としてビタミンE等も会合している複雑
な複合体である。リポ蛋白質は、その粒径や含有される
アポ蛋白質の種類に基づき、カイロミクロン(以下「C
M」と記載する)、超低比重リポ蛋白質(以下「VLD
L」と記載する)、低比重リポ蛋白質(以下「LDL」
と記載する)、高比重リポ蛋白質(以下「HDL」と記
載する)等に分類される。そして、例えばヒト血液試料
中のCM、VLDL、LDL等に含まれるコレステロー
ル、トリグリセリド(中性脂肪)及びリン脂質の含有量
について量比を分析することが、虚血性心疾患、肝疾
患、糖尿病等の疾病と脂質代謝異常との関連を解明する
上で重要になっている。2. Description of the Related Art Lipoprotein is a complex substance in which cholesterol, triglyceride (neutral fat), phospholipid and apoprotein are associated, and sometimes vitamin E and the like are also associated. Lipoproteins can be classified into chylomicrons (hereinafter referred to as "C") based on their particle size and the type of apoprotein contained.
M), very low density lipoprotein (hereinafter referred to as “VLD”).
L "), low density lipoprotein (hereinafter" LDL ")
HDL) and high-density lipoprotein (hereinafter referred to as “HDL”). For example, analyzing the ratio of cholesterol, triglyceride (neutral fat) and phospholipid contained in CM, VLDL, LDL, etc. in a human blood sample can be performed by analyzing ischemic heart disease, liver disease, diabetes, etc. It has become important in elucidating the relationship between diseases of the stomach and abnormalities in lipid metabolism.
【0003】CM、VLDL、LDL等の量比を分析す
るためには、血液試料等をゲルろ過クロマトグラフィ
ー、イオン交換クロマトグラフィー又は逆相クロマトグ
ラフィー等の液体クロマトグラフに供してリポ蛋白質を
粒径、電荷又は疎水性等に基づきCM、VLDL及びL
DL等に分離した後、各分離画分中のコレステロール、
トリグリセリド(中性脂肪)又はリン脂質等を検出・測
定して分析するという、簡便で再現性の良い液体クロマ
トグラフ法を用いるのが一般的である。液体クロマトグ
ラフ法では、分離カラムによる分離の後に、コレステロ
ール、リン脂質又はトリグリセリドと反応する反応試薬
を混合し、反応コイルで反応させてから検出器で検出・
測定してクロマトグラムを得、このクロマトグラムから
分析を行う。[0003] In order to analyze the quantitative ratio of CM, VLDL, LDL, etc., a blood sample or the like is subjected to liquid chromatography such as gel filtration chromatography, ion exchange chromatography or reverse phase chromatography to reduce the lipoprotein particle size. CM, VLDL and L based on charge, hydrophobicity, etc.
After separation into DL, etc., cholesterol in each separated fraction,
In general, a simple and reproducible liquid chromatographic method of detecting, measuring and analyzing triglyceride (neutral fat) or phospholipid is used. In liquid chromatography, after separation by a separation column, a reaction reagent that reacts with cholesterol, phospholipid or triglyceride is mixed, reacted with a reaction coil, and then detected with a detector.
The chromatogram is obtained by the measurement, and the analysis is performed from the chromatogram.
【0004】[0004]
【発明が解決しようとする課題】前記の通り、現在のと
ころでは、液体クロマトグラフ法を用いて液試料中に含
まれるCM、VLDL、LDL等のリポ蛋白質について
コレステロール、トリグリセリド(中性脂肪)又はリン
脂質等の量比を分析することで虚血性心疾患、肝疾患、
糖尿病等の疾病と脂質代謝異常との関連の解明が進めら
れている。ところが、一度の液体クロマトグラフ操作に
よりリポ蛋白質を粒径、電荷又は疎水性に基づきCM、
VLDL、LDL等に分離することは容易であるが、こ
れら各分離画分中のコレステロール量、トリグリセリド
(中性脂肪)量及びリン脂質量を同時に検出・測定しよ
うとすると、例えばコレステロールの検出・測定のため
の反応試薬がトリグリセリド(中性脂肪)やリン脂質の
検出・測定に影響を与えてしまうという課題がある。As described above, at present, lipoproteins such as CM, VLDL, and LDL contained in a liquid sample are determined by cholesterol, triglyceride (neutral fat) or lipoprotein contained in a liquid sample by liquid chromatography. By analyzing the ratio of phospholipids etc., ischemic heart disease, liver disease,
Elucidation of the relationship between diseases such as diabetes and abnormalities in lipid metabolism has been promoted. However, lipoproteins can be converted into CM,
Although separation into VLDL, LDL and the like is easy, if it is attempted to simultaneously detect and measure the cholesterol amount, triglyceride (neutral fat) amount and phospholipid amount in each of these separated fractions, for example, detection and measurement of cholesterol However, there is a problem that the reaction reagent for the reaction affects the detection and measurement of triglyceride (neutral fat) and phospholipid.
【0005】このため、液体クロマトグラフで分離され
る分離画分毎にコレステロール、リン脂質、トリグリセ
リド(中性脂肪)を測定するためには、同一試料を最低
3回液体クロマトグラフに供し、第1回目の操作ではコ
レステロールを、第2回目の操作ではトリグリセリド
(中性脂肪)を、そして第3回目の操作ではリン脂質を
測定するための反応試薬を混合、反応させ、検出器で検
出・測定してクロマトグラムを得る必要があった。Therefore, in order to measure cholesterol, phospholipid, and triglyceride (neutral fat) for each of the separated fractions separated by liquid chromatography, the same sample is subjected to liquid chromatography at least three times. In the second operation, cholesterol, in the second operation, triglyceride (neutral fat), and in the third operation, a reaction reagent for measuring phospholipid is mixed and reacted, and detected and measured by a detector. Needed to obtain a chromatogram.
【0006】この結果、各クロマトグラフ操作に先立っ
て、分離カラムから溶出する成分に混合、反応させる反
応試薬を準備、交換等するか、あるいは液体クロマトグ
ラフ装置を複数台(例えば3台)用意し、各装置に異な
る反応試薬をセットしておき、順次又は一度に全装置を
用いて分析を行う必要があった。As a result, prior to each chromatographic operation, a reaction reagent to be mixed and reacted with a component eluted from the separation column is prepared and exchanged, or a plurality of liquid chromatograph devices (for example, three) are prepared. In addition, it is necessary to set different reaction reagents in each device and perform analysis using all the devices sequentially or at once.
【0007】上記のようにしてリポ蛋白質の分析を行っ
た場合には、分析準備に時間がかかり又は分析に用いる
装置台数が増えるという課題以外に、試料を複数回の液
体クロマトグラフ操作に供さなければならないために比
較的大量の試料が必要になるという課題もある。また更
には、1台の液体クロマトグラフを用いて複数回の操作
を行う場合には各操作を均一に行なわないと得られたク
ロマトグラム同士を比較することができなくなる可能性
が生じる。複数台の液体クロマトグラフ装置を使用する
場合にも、装置間、例えば分離カラムの劣化状態、送液
量、検出器の検出感度等を均一に保たないと同様の課題
が生じる。[0007] When the lipoprotein is analyzed as described above, the sample is subjected to a plurality of liquid chromatograph operations, in addition to the problem that it takes time to prepare the analysis or increases the number of apparatuses used for the analysis. There is also a problem that a relatively large amount of sample is required because of the necessity. Furthermore, when a plurality of operations are performed using one liquid chromatograph, there is a possibility that the obtained chromatograms cannot be compared unless each operation is performed uniformly. Even when a plurality of liquid chromatograph devices are used, the same problem occurs unless uniformity is maintained between the devices, for example, the state of deterioration of the separation column, the amount of liquid sent, the detection sensitivity of the detector, and the like.
【0008】そこで本発明の目的は、反応試薬の交換を
行う必要がなく、1台の液体クロマトグラフ装置を使用
した一回の液体クロマトグラフ操作で、試料中に含まれ
るCM、VLDL、LDL等のリポ蛋白質についてコレ
ステロール、トリグリセリド(中性脂肪)、リン脂質等
の量比を分析し得る液体クロマトグラフィー装置を提供
することにある。Accordingly, an object of the present invention is to eliminate the need for exchanging reaction reagents, and to carry out CM, VLDL, LDL, etc. contained in a sample by one liquid chromatograph operation using one liquid chromatograph. An object of the present invention is to provide a liquid chromatography apparatus capable of analyzing the lipoprotein of the present invention for the quantitative ratio of cholesterol, triglyceride (neutral fat), phospholipid and the like.
【0009】[0009]
【課題を解決するための手段】前記目的を達成するため
に成された本発明は、試料中のリポ蛋白質を分析する液
体クロマトグラフィー装置であって、単一流路を用いて
試料を分離カラムに導入し、分離カラムから溶出した成
分を分割してそれぞれが検出器を備える複数の流路に導
き、各流路に導かれた成分ごとに前記検出器を用いてリ
ポ蛋白質の検出・測定を行うようにした装置である。以
下、本発明の試料中のリポ蛋白質を分析する液体クロマ
トグラフィー装置(以下単に「本発明の装置」等と記載
する)を詳細に説明する。Means for Solving the Problems The present invention made to achieve the above object is a liquid chromatography apparatus for analyzing a lipoprotein in a sample, wherein the sample is applied to a separation column using a single flow path. The components introduced and eluted from the separation column are divided and led to a plurality of flow paths each having a detector, and the lipoprotein is detected and measured using the detector for each of the components guided to each flow path. It is the device which did in this way. Hereinafter, a liquid chromatography apparatus for analyzing lipoprotein in a sample of the present invention (hereinafter simply referred to as “the apparatus of the present invention”) will be described in detail.
【0010】本発明の装置には、試料中のリポ蛋白質を
粒径、電荷又は疎水性に基づいてCM、VLDL又はL
DL等に分離するための分離カラムが装備される。分離
カラムは、例えばリポ蛋白質の粒径に基づいてリポ蛋白
質を分離しようとする場合にはゲルろ過用カラム、リポ
蛋白質の電荷に基づいてリポ蛋白質を分離しようとする
場合にはイオン交換カラム、そしてリポ蛋白質の疎水性
に基づいてリ分離しようとする場合には逆相カラムを用
いればよい。各種のカラムとしては市販されているもの
(例えばゲルろ過用カラムであれば、東ソー(株)製、
商品名TSKgel Lipopropak XL等)
を使用することが例示できる。[0010] The apparatus of the present invention uses a lipoprotein in a sample based on CM, VLDL or L based on particle size, charge or hydrophobicity.
A separation column for separation into DL or the like is provided. Separation columns are, for example, gel filtration columns when trying to separate lipoproteins based on lipoprotein particle size, ion exchange columns when trying to separate lipoproteins based on lipoprotein charge, and A reverse phase column may be used for re-separation based on the hydrophobicity of the lipoprotein. Various types of columns are commercially available (for example, gel filtration columns manufactured by Tosoh Corporation)
Product name TSKgel Lipopropak XL, etc.)
Can be used.
【0011】本発明の装置では、血清、血漿、細胞培養
上清等の試料を単一流路を用いて分離カラムに導入す
る。ここで試料を液体クロマトグラフ装置に導入するに
は通常のオートサンプラー等を、試料や溶離液の送液に
は通常のポンプを、単一流路を形成する管には通常の液
体クロマトグラフィーで用いるもののうちリポ蛋白質や
後述する反応試薬に対して不活性なものを、それぞれ使
用することができる。なお、溶離液は、用いる分離カラ
ムの種類に応じて適宜決定する。例えばゲル濾過用カラ
ムを用いるのであれば、100mM以上の塩化ナトリウ
ム、硫酸ナトリウム、硝酸ナトリウム、酢酸ナトリウ
ム、過塩素酸ナトリウム、硝酸アンモニウム等の塩成分
をイオン的相互作用の低減を目的として加えることが例
示できる。In the apparatus of the present invention, a sample such as serum, plasma, cell culture supernatant, etc. is introduced into a separation column using a single channel. Here, a normal autosampler or the like is used to introduce the sample into the liquid chromatograph, a normal pump is used for sending the sample and the eluent, and a normal liquid chromatography is used for the tube forming the single flow path. Among them, those inactive against lipoproteins and reaction reagents described below can be used. The eluent is appropriately determined according to the type of separation column used. For example, if a gel filtration column is used, a salt component of 100 mM or more, such as sodium chloride, sodium sulfate, sodium nitrate, sodium acetate, sodium perchlorate, and ammonium nitrate, may be added for the purpose of reducing ionic interactions. it can.
【0012】本発明の装置では、分離カラムから溶出し
た成分を2以上に分割して、それぞれが検出器を備える
複数の流路に導き、各流路に導かれた成分ごとにこの検
出器を用いてリポ蛋白質の検出・測定を行うようにした
点に特徴を有する。ここで本発明の装置における分割と
は、試料に含まれるリポ蛋白質を粒径、電荷又は疎水性
に基づいて分離した状態で2以上に分けることを意味す
る。従って、分割された成分は完全に同一の組成であ
り、かつ、各組成の比率完全に同一である。In the apparatus of the present invention, the component eluted from the separation column is divided into two or more parts, each of which is led to a plurality of flow paths provided with a detector, and this detector is provided for each of the components led to each flow path. It is characterized in that lipoprotein is detected and measured by using the method. Here, the division in the apparatus of the present invention means that the lipoprotein contained in the sample is divided into two or more in a state of being separated based on the particle size, charge or hydrophobicity. Therefore, the divided components have completely the same composition, and the ratio of each composition is completely the same.
【0013】分離カラムから溶出した成分を分割してそ
れぞれが検出器を備える複数の流路に導くために、分離
カラムの後ろ(下流)側にはスプリッターが配置され
る。スプリッターは、分離カラムからの溶出成分を2以
上に分割できるものであれば良いが、分割する比率を調
整できるスプリッター(例えばUPCHURCH SC
IENTIFIC INC.製、商品名マイクロスプリ
ッターP−450)を用いることが好ましい。かかる分
割比率を調整できるスプリッターであれば、例えば、比
較的高感度で検出・測定ができるものについて検出・測
定を行う流路への流量を少なく、逆に比較的感度の低い
検出・測定を行う流路への流量を多くすることが可能と
なるからである。また本発明において流路を3分割する
場合には、3分割用のスプリッターを用いる以外に2分
割用のスプリッターを2台接続して使用することもでき
る。[0013] A splitter is arranged behind (downstream) the separation column in order to divide the components eluted from the separation column and guide them to a plurality of flow paths each having a detector. The splitter may be any as long as it can split the eluted component from the separation column into two or more. A splitter (for example, UPCHURCH SC) capable of adjusting the splitting ratio is used.
IENTIFIC INC. It is preferable to use a micro splitter (manufactured and trade name: Micro Splitter P-450). If the splitter can adjust the splitting ratio, for example, for those that can be detected and measured with relatively high sensitivity, the flow rate to the channel for performing detection and measurement is small, and on the contrary, detection and measurement with relatively low sensitivity are performed. This is because the flow rate to the flow path can be increased. In the present invention, when the flow path is divided into three parts, two splitters for two divisions can be connected and used instead of using the splitter for three divisions.
【0014】スプリッターの後ろ(下流)側に接続する
流路には、前記同様、通常の液体クロマトグラフィーで
使用する管を用いることができる。流路の数は、2本以
上であれば良いが、分離カラムでリポ蛋白質の粒径、電
荷又は疎水性に基づいて分離したCM、VLDL又はL
DL等について、後に何種類の測定を行うかにより適宜
決定できる。現在のところ、コレステロール、トリグリ
セリド(中性脂肪)及びリン脂質の量比に関する知見が
虚血性心疾患、肝疾患、糖尿病等の疾病と脂質代謝異常
との関連の解明するうえで重要であるとされていること
から、分離カラムから溶出した成分を3分割して3本の
流路に導き、各流露に導かれた成分ごとにコレステロー
ル、トリグリセリド(中性脂肪)又はリン脂質の測定を
行い得るように3本の流路をスプリッターに接続するこ
とが特に好ましい。むろん、前記以外に、例えばビタミ
ンE等の検出・測定が必要となった場合には、スプリッ
ターに接続する流路の本数を4本以上に増やせば良い。As described above, a tube used in ordinary liquid chromatography can be used for the flow path connected to the back (downstream) side of the splitter. The number of channels may be two or more, but CM, VLDL or L separated on a separation column based on the particle size, charge or hydrophobicity of lipoprotein.
DL and the like can be appropriately determined depending on how many types of measurements are performed later. At present, knowledge on the ratio of cholesterol, triglyceride (triglyceride) and phospholipid is considered to be important for elucidating the relationship between diseases such as ischemic heart disease, liver disease and diabetes and abnormal lipid metabolism. Therefore, the components eluted from the separation column are divided into three and led to three flow paths, and cholesterol, triglyceride (neutral fat) or phospholipid can be measured for each component led to each flow. It is particularly preferable to connect three flow paths to the splitter. Of course, in addition to the above, when it is necessary to detect and measure, for example, vitamin E, the number of channels connected to the splitter may be increased to four or more.
【0015】各流路に導かれた成分ごとに行うコレステ
ロール、トリグリセリド(中性脂肪)又はリン脂質の測
定は、分割後、各流路に導かれた成分に対し、コレステ
ロール反応試薬、トリグリセリド(中性脂肪)反応試薬
又はリン脂質反応試薬等を混合、反応させた後に検出器
に導入し、各反応試薬との反応の様子を測定することが
例示できる。即ち、例えば分離カラムから溶出した成分
を3分割して第1、第2又は第3の流路に導き、第1の
流路についてはコレステロール反応試薬を混合、反応さ
せて測定を行い、第2の流路についてはトリグリセリド
(中性脂肪)反応試薬を混合、反応させて測定を行い、
そして第3の流路についてはリン脂質反応試薬を混合、
反応させて測定を行うことが具体的に例示できる。In the measurement of cholesterol, triglyceride (neutral fat) or phospholipid performed for each component guided to each flow channel, the cholesterol reaction reagent, triglyceride (medium) For example, after mixing and reacting a reactive reagent or a phospholipid reaction reagent, the mixture is introduced into a detector, and the state of the reaction with each reaction reagent is measured. That is, for example, the component eluted from the separation column is divided into three and guided to the first, second or third flow path, and the first flow path is mixed and reacted with a cholesterol reaction reagent to perform measurement. For the flow path, triglyceride (neutral fat) reagent is mixed, reacted and measured.
Then, for the third channel, a phospholipid reaction reagent is mixed,
A specific example is that measurement is performed by reacting.
【0016】上記具体例を実施するためには、例えば、
各流路の検出器に至る前の部分に反応コイルを配置し、
この反応コイルの直前に、各反応試薬を貯蔵する液溜め
からの流路を送液ポンプを介して接続する等すれば良
い。In order to implement the above example, for example,
A reaction coil is placed in the part of each flow path before reaching the detector,
Immediately before this reaction coil, a flow path from a reservoir for storing each reaction reagent may be connected via a liquid sending pump.
【0017】上記各反応試薬について一例を記載すれ
ば、コレステロール反応試薬ではコレステロールオキシ
ダーゼ、コレステロールエステラーゼを含む試薬液を、
トリグリセリド(中性脂肪)反応試薬ではリポプロテイ
ンリパーゼ、グリセロールオキシダーゼを含む試薬液
を、リン脂質反応試薬ではホスホリパーゼ、コリンオキ
シダーゼを含む試薬液を例示できる。ここで反応試薬
は、リポ蛋白質を分解してコレステロール、トリグリセ
リド又はリン脂質を対応する反応試薬と反応可能な状態
とするための界面活性剤を含むことが好ましい。かかる
好ましい各反応試薬として、市販の試薬(コレステロー
ル反応試薬では、協和メディクス(株)製・商品名デタ
ミナーLTC、東洋紡(株)製・商品名コラスカラーリ
キッド、第一化学薬品(株)製・商品名ピュアオートS
CHO−N;トリグリセリド(中性脂肪)反応試薬で
は、協和メディクス(株)製・商品名デタミナーTG、
第一化学薬品(株)製・ピュアオートS TG−N)を
用いることもできる。As an example of each of the above-mentioned reaction reagents, a cholesterol reaction reagent contains a reagent solution containing cholesterol oxidase and cholesterol esterase.
A reagent solution containing lipoprotein lipase and glycerol oxidase can be exemplified as the triglyceride (neutral fat) reaction reagent, and a reagent solution containing phospholipase and choline oxidase can be exemplified as the phospholipid reaction reagent. Here, the reaction reagent preferably contains a surfactant for decomposing the lipoprotein so that cholesterol, triglyceride or phospholipid can react with the corresponding reaction reagent. As each of such preferable reaction reagents, commercially available reagents (for cholesterol reaction reagents, Determiner LTC manufactured by Kyowa Medix Co., Ltd., Collas Color Liquid manufactured by Toyobo Co., Ltd., manufactured by Daiichi Kagaku Co., Ltd.) Name Pure Auto S
CHO-N; a triglyceride (neutral fat) reaction reagent manufactured by Kyowa Medix Co., Ltd.
Pure Auto S TG-N manufactured by Daiichi Pure Chemicals Co., Ltd. can also be used.
【0018】各流路が装備する検出器は、コレステロー
ル、トリグリセリド(中性脂肪)、リン脂質等の成分を
検出してその量を測定し得るものであれば特に制限はな
い。例えば前記したようにコレステロール反応試薬、ト
リグリセリド(中性脂肪)反応試薬又はリン脂質反応試
薬等を混合、反応させた後に検出・測定を行うのであれ
ば、同一の吸光度検出器等を2台以上用いることも可能
である。The detector provided in each channel is not particularly limited as long as it can detect components such as cholesterol, triglyceride (neutral fat) and phospholipid and measure the amount. For example, as described above, if detection and measurement are performed after mixing and reacting a cholesterol reagent, a triglyceride (neutral fat) reagent or a phospholipid reagent, two or more identical absorbance detectors are used. It is also possible.
【0019】本発明の装置では、分離カラムからの溶出
成分を分割する数(即ちスプリッターに接続する流露の
本数)、分割後のコレステロール等の検出・測定方式、
そして各流路が備える検出器の検出感度等を考慮したう
えで、分析に供する試料の量を決定することが好まし
い。例えば前記したような反応試薬を用いる場合であっ
て、流路を2分割するのであれば、少なくとも15μ
l、好ましくは20μl程度の試料を用いることが好ま
しい。このように、分離カラムからの溶出成分を均等に
分割するのであれば、各流路に10μlの成分が導かれ
るように、流路の本数×10μlの試料を用いることが
一応の目安として例示できる。In the apparatus of the present invention, the number of components to be eluted from the separation column is divided (that is, the number of dewdrops connected to the splitter), the method of detecting and measuring cholesterol and the like after division,
Then, it is preferable to determine the amount of the sample to be analyzed in consideration of the detection sensitivity and the like of the detector provided in each channel. For example, when the above-mentioned reaction reagent is used and the flow path is divided into two, at least 15 μm is used.
It is preferable to use a sample of about 1, preferably about 20 μl. As described above, if the eluted components from the separation column are equally divided, the use of a sample of the number of flow channels × 10 μl can be exemplified as a tentative guide so that 10 μl of the components is guided to each flow channel. .
【0020】[0020]
【発明の実施の形態】以下、本発明を図面に記載した実
施の形態及び実施例を用いてより詳細に説明するが、本
発明はこれらに限定されるものではない。DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present invention will be described in more detail with reference to embodiments and examples shown in the drawings, but the present invention is not limited to these.
【0021】図1は、本発明装置の概略を説明するため
の図である。1は溶離液溜め、2は脱気装置(デガッ
サ)、3は送液ポンプ、4はオートサンプラー、5はフ
ィルター、6は分離カラム(本例では2本のカラムを直
列に配置して分離能を向上した)、7はカラムオーブ
ン、8は流路2分割用のスプリッター、9は抵抗管、1
0及び11は反応コイル、13及び14は検出器、15
は反応試薬用送液ポンプ、16はエアートラップ、17
はコレステロール反応試薬溜め、18はトリグリセリド
反応試薬溜めをそれぞれ示す。FIG. 1 is a diagram for explaining the outline of the apparatus of the present invention. 1 is an eluent reservoir, 2 is a degasser (degasser), 3 is a liquid sending pump, 4 is an autosampler, 5 is a filter, and 6 is a separation column (in this example, two columns are arranged in series and the separation capacity is , 7 is a column oven, 8 is a splitter for dividing the flow path into two, 9 is a resistance tube, 1
0 and 11 are reaction coils, 13 and 14 are detectors, 15
Is a liquid sending pump for a reaction reagent, 16 is an air trap, 17
Denotes a cholesterol reaction reagent reservoir, and 18 denotes a triglyceride reaction reagent reservoir.
【0022】オートサンプラーによって分離カラムに至
るまでの単一流路に導入された試料は、分離カラムでリ
ポ蛋白質の粒径、電荷又は疎水性に基づき分離され、溶
出する。溶出した成分はスプリッターにて2分割され、
それぞれ異なる流路に導入される。一方の流路では、分
割された成分に対してコレステロール反応試薬が混合さ
れ、反応コイルで反応された後、検出器に導かれてコレ
ステロールの検出・測定が行われる。他方の流路では分
割された成分に対してトリグリセリド反応試薬が混合さ
れ、反応コイルで反応された後、検出器に導かれてトリ
グリセリドの検出・測定が行われる。The sample introduced into the single channel up to the separation column by the autosampler is separated and eluted by the separation column based on the particle size, charge or hydrophobicity of the lipoprotein. The eluted components are split into two by a splitter,
Each is introduced into a different flow path. In one flow path, a cholesterol reaction reagent is mixed with the divided components and reacted by a reaction coil, and then guided to a detector to detect and measure cholesterol. In the other flow path, a triglyceride reaction reagent is mixed with the divided components and reacted by a reaction coil, and then guided to a detector to detect and measure triglyceride.
【0023】実施例1 図1に示した装置を用いて、ヒト血清中のリポ蛋白質分
析を行った。なお、図1における送液ポンプ3としては
市販の製品(東ソー(株)製、商品名CCPS)、反応
試薬用送液ポンプ15としては市販の製品(東ソー
(株)製、商品名CCPM−2)、オートサンプラー4
としては市販の製品(東ソー(株)製、商品名AS−8
020)、フィルター5としては市販の製品(東ソー
(株)製、フィルターK)、カラム6としては市販の製
品(東ソー(株)製、TSKgel Lipoprop
ak XL、カラムサイズ;7.8mmI.D.×30
cm)を用いた。Example 1 Using the apparatus shown in FIG. 1, lipoprotein analysis in human serum was performed. A commercially available product (manufactured by Tosoh Corporation, trade name: CCPS) is used as the liquid sending pump 3 in FIG. 1, and a commercially available product (manufactured by Tosoh Corporation, trade name: CCPM-2) is used as the liquid sending pump 15 for the reaction reagent. ), Autosampler 4
Are commercially available products (manufactured by Tosoh Corporation, trade name AS-8)
020), a commercially available product (Filter K, manufactured by Tosoh Corporation) as the filter 5, and a commercially available product (TSKgel Lipoprop, manufactured by Tosoh Corporation) as the column 6.
ak XL, column size; D. × 30
cm) was used.
【0024】抵抗管9としては0.2mmI.D.×2
mサイズのステンレス製管を、反応コイル10、11と
してはそれぞれ0.4mmI.D.×7.5m、0.4
mmI.D.×40mのサイズのテフロン製管を用い
た。The resistance tube 9 has a diameter of 0.2 mmI. D. × 2
m-sized stainless steel tubes were used as the reaction coils 10 and 11 at 0.4 mmI. D. × 7.5m, 0.4
mmI. D. A Teflon tube having a size of × 40 m was used.
【0025】カラムオ−ブン7とリアクター12として
は共に市販の製品(東ソー(株)製、商品名CO−80
20)を用い、それぞれの設定温度を25℃、37℃と
した。検出器13、14としてはそれぞれ市販の製品
(東ソー(株)製、商品名UV−8020、UV−80
00)を用い、それぞれの検出波長を共に550nmと
した。Both the column oven 7 and the reactor 12 are commercially available products (manufactured by Tosoh Corporation, trade name CO-80).
20), and the set temperatures were 25 ° C. and 37 ° C., respectively. As the detectors 13 and 14, commercially available products (trade names UV-8020, UV-80, manufactured by Tosoh Corporation)
00), and the respective detection wavelengths were set to 550 nm.
【0026】エアートラップ16としては市販の製品
(東ソー(株)製、商品名エアートラップG)、デガッ
サー2としては市販の製品(東ソー(株)製、商品名S
D−8022)を用いた。The air trap 16 is a commercially available product (trade name: Air Trap G, manufactured by Tosoh Corporation), and the degasser 2 is a commercially available product (trade name: S, manufactured by Tosoh Corporation)
D-8022) was used.
【0027】溶離液1としては50mM トリス及び3
00mM酢酸ナトリウムを含むpH8.0の溶液を用
い、流速は0.60ml/分とした。スプリッター8と
しては市販の製品(UPCHURCH SCIENTI
FIC INC.製、商品名マイクロスプリッターP−
450)を用い、カラム分離後の溶出液を等量に分割す
るように調整した。Eluent 1 was 50 mM Tris and 3
A pH 8.0 solution containing 00 mM sodium acetate was used, and the flow rate was 0.60 ml / min. As the splitter 8, a commercially available product (UPCHURCH SCIENTI)
FIC INC. Product name, micro splitter P-
450), the eluate after column separation was adjusted to be divided into equal volumes.
【0028】コレステロール反応試薬17については、
市販の試薬(第一化学薬品(株)製、商品名ピュアオー
トS CHO−Nの試薬1と2をあらかじめ2対1の割
合で混合した反応試薬)を用い、その流速は0.15m
l/分とした。トリグリセリド(中性脂肪)反応試薬1
8については、(第一化学薬品(株)製、商品名ピュア
オートS TG−Nの試薬1と2をあらかじめ2対1の
割合で混合した反応試薬)用い、その流速は0.30m
l/分とした。As for the cholesterol reaction reagent 17,
A commercially available reagent (a reaction reagent obtained by mixing reagents 1 and 2 of Pure Auto S CHO-N (trade name, manufactured by Daiichi Pure Chemicals Co., Ltd.) at a ratio of 2: 1 in advance) was used at a flow rate of 0.15 m.
1 / min. Triglyceride (neutral fat) reaction reagent 1
For No. 8, (reaction reagent prepared by mixing the reagents 1 and 2 of Pure Auto S TG-N (trade name, manufactured by Daiichi Pure Chemical Co., Ltd.) at a ratio of 2: 1 in advance) was used, and the flow rate was 0.30 m.
1 / min.
【0029】正常人血清をオートサンプラー4にて15
μl装置に供してカラム6で分離し、スプリッター8で
等量に分割した。うち一方をコレステロール反応試薬と
混合し反応コイル10にて反応させ、検出器13により
550nmの波長で検出・測定した。分割した他方をト
リグリセリド(中性脂肪)反応試薬と混合し反応コイル
11にて反応させ、検出器14により550nmの波長
で検出・測定した。結果を図2及び図3に示す。[0029] Serum from a normal human was analyzed by an autosampler 4 for 15 minutes.
The mixture was applied to a μl apparatus, separated by a column 6, and divided into equal parts by a splitter 8. One of them was mixed with a cholesterol reaction reagent, reacted with the reaction coil 10, and detected and measured by the detector 13 at a wavelength of 550 nm. The other part was mixed with a triglyceride (neutral fat) reaction reagent, reacted with the reaction coil 11, and detected and measured by the detector 14 at a wavelength of 550 nm. The results are shown in FIGS.
【0030】図2はコレステロールに関する検出・測定
結果(クロマトグラム)を示すものである。LDLとH
DLのピークは良好に確認でき、分析に供した試料が1
5μlと微量であったにもかかわらず、VLDLについ
てもLDLのピーク前部分に分離が不完全ではあるが、
ピークが確認できた。FIG. 2 shows the results of detection and measurement (chromatogram) of cholesterol. LDL and H
The DL peak can be confirmed well, and the sample subjected to analysis is 1
Despite the small volume of 5 μl, VLDL is not completely separated at the LDL peak,
A peak was confirmed.
【0031】図3はトリグリセリド(中性脂肪)の検出
・測定結果(クロマトグラム)を示すものである。C
M、LDL、HDL、FG(遊離グリセロール)のピー
クは良好に確認でき、分析に供した試料が15μlと微
量であったにもかかわらず、VLDLについてもLDL
のピーク前部分に分離が不完全ではあるが、ピークが確
認できた。FIG. 3 shows the results of detection and measurement (chromatogram) of triglyceride (neutral fat). C
The peaks of M, LDL, HDL, and FG (free glycerol) could be confirmed well, and even though the amount of the sample used for analysis was as small as 15 μl, the VLDL was also LDL.
Although the separation was incomplete before the peak of, a peak was confirmed.
【0032】[0032]
【発明の効果】本発明によれば、反応試薬の交換を行う
必要がなく、1台の液体クロマトグラフ装置を使用した
一回の液体クロマトグラフ操作で試料中に含まれるC
M、VLDL、LDL等リポ蛋白質について、コレステ
ロール、トリグリセリド(中性脂肪)又はリン脂質の量
を検出・測定し、分析し得る液体クロマトグラフィー装
置が提供される。According to the present invention, there is no need to exchange reaction reagents, and C contained in a sample can be obtained by one liquid chromatograph operation using one liquid chromatograph.
Provided is a liquid chromatography apparatus capable of detecting, measuring, and analyzing the amount of cholesterol, triglyceride (neutral fat) or phospholipid for lipoproteins such as M, VLDL, and LDL.
【0033】この結果、リポ蛋白質を分離カラムにて分
離した後、溶出した成分を複数の流路に導き、各流路ご
とに装備された検出器を用いて検出・測定を行う本発明
の分析装置によれば、1台の装置のみを用いた場合であ
っても、反応試薬の交換を行うことなく、一回の操作で
試料中に含まれるリポ蛋白質についてコレステロール
量、リン脂質量、トリグリセリド(中性脂肪)量を検出
・測定し、最終的には試料中にCM、VLDL又はLD
Lといったリポ蛋白質毎にコレステロール、トリグリセ
リド(中性脂肪)又はリン脂質がいかなる量比で存在し
ているのかという分析を可能にすることができる。As a result, after the lipoproteins are separated by the separation column, the eluted components are guided to a plurality of flow paths, and the detection and measurement are performed using the detector provided for each flow path. According to the apparatus, even if only one apparatus is used, the cholesterol amount, phospholipid amount, triglyceride ( Triglyceride) is detected and measured, and finally CM, VLDL or LD
For each lipoprotein such as L, it is possible to analyze what amount of cholesterol, triglyceride (neutral fat) or phospholipid is present.
【0034】従って本発明の装置によれば、同様の分析
結果を得るために複数回のクロマトグラフィ操作を行っ
たり複数台の液体クロマトグラフ装置を用いなければな
らない従来の方法と比較して、より短時間に、より少な
い試料を用いるのみで分析結果を得ることが可能とな
る。Therefore, according to the apparatus of the present invention, a shorter period of time is required as compared with the conventional method in which a plurality of chromatographic operations must be performed or a plurality of liquid chromatograph apparatuses must be used in order to obtain the same analysis results. It is possible to obtain an analysis result by using less sample in time.
【図1】図1は、本発明の装置の概略を説明するための
図である。FIG. 1 is a diagram for explaining an outline of an apparatus of the present invention.
【図2】図2は、実施例1におけるコレステロール検出
・測定の結果(クロマトグラム)であり、横軸は試料を
装置に供してからの時間(分)を示す。図中のVLD
L、LDL、HDLは、それぞれ超低比重リポ蛋白質、
低比重リポ蛋白質、高比重リポ蛋白質を示す。FIG. 2 is a result (chromatogram) of cholesterol detection / measurement in Example 1, and the horizontal axis represents a time (minute) after the sample was supplied to the apparatus. VLD in the figure
L, LDL, and HDL are very low density lipoproteins,
Shows low density lipoprotein and high density lipoprotein.
【図3】図3は、実施例1におけるトリグリセリド(中
性脂肪)検出・測定の結果(クロマトグラム)であり、
横軸は試料を装置に供してからの時間(分)を示す。図
中のCM、VLDL、LDL、HDL、FGは、それぞ
れカイロミクロン、超低比重リポ蛋白質、低比重リポ蛋
白質、高比重リポ蛋白質、遊離グリセロールを示す。FIG. 3 is a result (chromatogram) of detection and measurement of triglyceride (neutral fat) in Example 1.
The horizontal axis indicates the time (minutes) after the sample was supplied to the apparatus. CM, VLDL, LDL, HDL, and FG in the figure represent chylomicron, very low density lipoprotein, low density lipoprotein, high density lipoprotein, and free glycerol, respectively.
1溶離液、2デガッサー、3送液ポンプ、4オートサン
プラー、5フィルター、6分離カラム、7カラムオーブ
ン(恒温器)、8スプリッター、9抵抗管、10・11
反応コイル、12リアクター(恒温器)、13・14検
出器、15反応試薬用送液ポンプ、16エアートラッ
プ、17コレステロール反応試薬、18トリグリセリド
反応試薬1 eluent, 2 degasser, 3 feed pump, 4 autosampler, 5 filter, 6 separation column, 7 column oven (incubator), 8 splitter, 9 resistance tube, 10.11
Reaction coil, 12 reactors (constant temperature chamber), 13/14 detector, 15 liquid supply pump for reaction reagent, 16 air trap, 17 cholesterol reaction reagent, 18 triglyceride reaction reagent
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) G01N 33/50 G01N 33/50 U 33/68 33/68 33/92 33/92 A C Z // C12M 1/34 C12M 1/34 E ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) G01N 33/50 G01N 33/50 U 33/68 33/68 33/92 33/92 A CZ // C12M 1/34 C12M 1/34 E
Claims (2)
トグラフィー装置であって、単一流路を用いて試料を分
離カラムに導入し、分離カラムからの溶出成分を分割し
てそれぞれが検出器を備える複数の流路に導き、各流路
に導かれた成分ごとに前記検出器を用いてリポ蛋白質の
検出・測定を行うようにした装置。1. A liquid chromatography apparatus for analyzing a lipoprotein in a sample, wherein the sample is introduced into a separation column by using a single flow path, components eluted from the separation column are divided, and a detector is used for each. An apparatus configured to guide to a plurality of flow paths provided and to detect and measure lipoprotein using the detector for each component guided to each flow path.
又は3である)分割してそれぞれが検出器を備えるn本
の流路をに導き、各流路に導かれた成分に対してコレス
テロール反応試薬、トリグリセリド(中性脂肪)反応試
薬又はリン脂質反応試薬の中から選ばれるn種の反応試
薬を混合、反応させた後、各流路ごとに検出器を用いて
リポ蛋白質の検出・測定を行うようにした請求項1の装
置。2. The method according to claim 1, wherein the components eluted from the separation column are n (n is 2).
Or 3) is divided into n flow paths each having a detector, and cholesterol reaction reagent, triglyceride (neutral fat) reaction reagent or phospholipid reaction is performed on the components guided to each flow path. 2. The apparatus according to claim 1, wherein n kinds of reaction reagents selected from the reagents are mixed and reacted, and then a lipoprotein is detected and measured using a detector for each channel.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP01677999A JP4058828B2 (en) | 1999-01-26 | 1999-01-26 | Lipoprotein analyzer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP01677999A JP4058828B2 (en) | 1999-01-26 | 1999-01-26 | Lipoprotein analyzer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000214150A true JP2000214150A (en) | 2000-08-04 |
JP4058828B2 JP4058828B2 (en) | 2008-03-12 |
Family
ID=11925695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP01677999A Expired - Fee Related JP4058828B2 (en) | 1999-01-26 | 1999-01-26 | Lipoprotein analyzer |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4058828B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002243745A (en) * | 2001-02-15 | 2002-08-28 | Tosoh Corp | Lipoprotein analyzer |
WO2004070379A1 (en) * | 2003-02-07 | 2004-08-19 | Shinichi Usui | Method of lipoprotein analysis and analytical program |
JP2005509860A (en) * | 2001-11-13 | 2005-04-14 | ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア | Ion mobility analysis of biological particles |
WO2007139204A1 (en) * | 2006-05-25 | 2007-12-06 | Tosoh Corporation | Method and apparatus for analysis of vitamin e in lipoprotein |
JP2008003082A (en) * | 2006-05-25 | 2008-01-10 | Tosoh Corp | Method and apparatus for analysis of vitamin e in lipoprotein |
-
1999
- 1999-01-26 JP JP01677999A patent/JP4058828B2/en not_active Expired - Fee Related
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002243745A (en) * | 2001-02-15 | 2002-08-28 | Tosoh Corp | Lipoprotein analyzer |
JP2005509860A (en) * | 2001-11-13 | 2005-04-14 | ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア | Ion mobility analysis of biological particles |
US7713744B2 (en) | 2001-11-13 | 2010-05-11 | The Regents Of The University Of California | Determining the risk of cardiovascular disease using ion mobility of lipoproteins |
US7851224B2 (en) | 2001-11-13 | 2010-12-14 | The Regents Of The University Of California | Method of assessing a lipid-related health risk based on ion mobility analysis of lipoproteins |
JP4705754B2 (en) * | 2001-11-13 | 2011-06-22 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア | Ion mobility analysis of biological particles |
WO2004070379A1 (en) * | 2003-02-07 | 2004-08-19 | Shinichi Usui | Method of lipoprotein analysis and analytical program |
WO2007139204A1 (en) * | 2006-05-25 | 2007-12-06 | Tosoh Corporation | Method and apparatus for analysis of vitamin e in lipoprotein |
JP2008003082A (en) * | 2006-05-25 | 2008-01-10 | Tosoh Corp | Method and apparatus for analysis of vitamin e in lipoprotein |
US7981683B2 (en) | 2006-05-25 | 2011-07-19 | Tosoh Corporation | Method and apparatus for analyzing vitamin E in lipoproteins |
US8076145B2 (en) | 2006-05-25 | 2011-12-13 | Tosoh Corporation | Method and apparatus for analyzing vitamin E in lipoproteins |
Also Published As
Publication number | Publication date |
---|---|
JP4058828B2 (en) | 2008-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gika et al. | Current practice of liquid chromatography–mass spectrometry in metabolomics and metabonomics | |
Oliver et al. | Localization of anionic phospholipids in Escherichia coli cells | |
Lindholm | Development and validation of HPLC methods for analytical and preparative purposes | |
Liu et al. | A strategy for sensitive, large scale quantitative metabolomics | |
Bartosova et al. | High throughput semiquantitative UHPSFC–MS/MS lipid profiling and lipid class determination | |
US12031962B2 (en) | Method for identifying a reagent during a process in an analysis system | |
JP2000214150A (en) | Analyzer for lipoprotein | |
JP2002139501A (en) | Method for analyzing and diagnosing lipoprotein subclass | |
EP3559656A1 (en) | Method for tracking a sample identity during a process in an analysis system | |
Qureshi et al. | Determination of cholesterol and triglycerides in serum lipoproteins using flow field-flow fractionation coupled to gas chromatography–mass spectrometry | |
EP4127705A1 (en) | Apparatus for analyzing laboratory samples, a cartridge for liquid chromatography and a method for heating a sample | |
Sandvik et al. | Routine supercritical fluid chromatography tandem mass spectrometry method for determination of vitamin K1 extracted from serum with a 96-well solid-phase extraction method | |
Adole et al. | Clinical utility of validated gas chromatography–ion trap mass spectrometry in patients with anticholinesterase pesticides poisoning | |
JP4644948B2 (en) | Lipoprotein analysis method | |
Busbee et al. | Separation and detection of lipoproteins in human serum by use of size-exclusion liquid chromatography: a preliminary report. | |
Markello et al. | High-performance liquid chromatography of lipids for the identification of human metabolic disease | |
Aurand et al. | Highly selective isolation and separation of 25-hydroxyvitamin D and 3-epi-25-hydroxyvitamin D metabolites from serum | |
JP3922028B2 (en) | Lipoprotein analysis method | |
US20190293611A1 (en) | Method for identifying a reagent during a process in an analysis system | |
Chi et al. | Evaporative light scattering quantification of natural products possessing a carbon–phosphorus bond | |
Kirchner | Thin-Layer Chromatography—Yesterday, Today, and Tomorrow | |
JP2002243745A (en) | Lipoprotein analyzer | |
Li et al. | Preparation of eicosapentaenoic acid ethyl ester from fish oil ethyl esters by continuous batch chromatography | |
Trap et al. | Gas chromatographic techniques for the analysis of chemical warfare agents | |
Majeski et al. | Fluorescent assay of total serum cholesterol, with use of gas-liquid chromatography to study saponification efficiency. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051206 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070809 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070821 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070911 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071016 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071029 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071127 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071210 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101228 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101228 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111228 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121228 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131228 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |